The American Medical Association (AMA), which is holding its annual meeting this week in Chicago, Illinois, has issued a call for intensified oversight of the pharmacy benefit manager (PBM) industry.
The American Medical Association (AMA), which is holding its annual meeting this week in Chicago, Illinois, has issued a call for intensified oversight of the pharmacy benefit manager (PBM) industry.
“It’s time to pull back the curtain on pharmacy benefit managers and how their practices negatively impact patients,” said Russell Kridel, MD, a member of the AMA board of trustees, in a statement announcing adoption of the policy. “How is it that PBMs and health plans profit from negotiated discounts on prescription drugs while patients pay co-pays based on high drug list prices that even the plans themselves are not paying? Because of market concentration and lack of transparency, patients and physicians are essentially powerless in the face of PBM pricing and coverage decisions,” he added.
According to the AMA, PBMs have similar roles to insurers, yet face no similar oversight, and are hampering policymakers’ efforts to reduce drug costs with their “byzantine” confidential contracts that drive increased costs for drugs without justification.
The new policy calls for active regulation of PBMs by state departments of insurance, application of rebates to drug prices at the point of sale, efforts to ensure that no patients are discriminated against in benefit design, and increased transparency in how direct and indirect remuneration fees are calculated.
AMA also calls for increased PBM transparency, including disclosure of information on topics like rebates, discounts, and utilization; pharmacy and therapeutics committee information; and formulary information, which AMA says should be made available to patients and prescribers at the point of care.
AMA says that it will develop model legislation addressing state-level regulation of PBMs for policymakers to use.
In addition to its attempt to promote policy solutions, the AMA also seeks to get patients involved; the organization’s new policy is linked with AMA’s TruthinRx campaign, a resource for patients to learn about what influences the price of drugs, how drug prices for products like insulin are increasing over time despite competition, and the role of PBMs in negotiating discounts and rebates with drug makers.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.